Peginterferon alfa-2b - Biologic Drug Details

Summary for peginterferon alfa-2b

Tradenames:	2
High Confidence Patents:	16
Applicants:	2
BLAs:	2
Recent Clinical Trials:	See clinical trials for peginterferon alfa-2b

Recent Clinical Trials for peginterferon alfa-2b

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Peking University People's Hospital	EARLY_PHASE1
Xiamen Humanity Hospital	NA
Xiamen Hospital of Traditional Chinese Medicine	NA

See all peginterferon alfa-2b clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for peginterferon alfa-2b Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for peginterferon alfa-2b Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,383,876	2032-03-29	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,577,154	2038-12-19	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,596,173	2038-05-03	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,626,100	2037-12-21	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,656,152	2037-11-08	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,844,066	2037-03-01	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	5,395,760	2010-05-10	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for peginterferon alfa-2b Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,383,876	2032-03-29	Patent claims search
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,577,154	2038-12-19	Patent claims search
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,596,173	2038-05-03	Patent claims search
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,626,100	2037-12-21	Patent claims search
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,656,152	2037-11-08	Patent claims search
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,844,066	2037-03-01	Patent claims search
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	10,933,061	2038-12-21	Patent claims search

International Patents for peginterferon alfa-2b

Country	Patent Number	Estimated Expiration
New Zealand	197572
Czechoslovakia	362787
Japan	H0693000
World Intellectual Property Organization (WIPO)	2010088548
Switzerland	657141
New Zealand	227327
Finland	105099

Supplementary Protection Certificates for peginterferon alfa-2b

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132000900852970	Italy
15/2000	Austria		PRODUCT NAME: ETANERCEPT; NAT. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: LI 55365 20000201
00C0015	France		PRODUCT NAME: ETANERCEPT; NAT. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: IKS- N 55365 20000201
SZ 15/2000	Austria		PRODUCT NAME: ETANERCEPT
0090011-8, 0091011-7	Sweden		NATIONAL REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: LI 55365 20000201
SPC/GB00/015	United Kingdom		PRODUCT NAME: ETANERCEPT; REGISTERED: CH 55365 20000201; UK EU/1/99/126/001 20000203
10075011	Germany		PRODUCT NAME: ENBREL-ETANERCEPT; NAT. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: CH (LI) 55365 20000201

Peginterferon alfa-2b Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Peginterferon Alfa-2b?

Peginterferon alfa-2b is a long-acting formulation of interferon alfa used primarily to treat hepatitis B and hepatitis C. Its market landscape is shaped by regulatory decisions, competitive shifts, and evolving treatment protocols. The drug's market dynamics are influenced by the following factors:

Regulatory Environment and Approvals

In 2018, the U.S. Food and Drug Administration (FDA) approved Peginterferon alfa-2b (brand name: PegIntron) for chronic hepatitis C, often in combination with ribavirin. However, with the advent of direct-acting antivirals (DAAs), the use of interferon-based therapies significantly declined. The European Medicines Agency (EMA) aligns with this trend, limiting indications to specific cases resistant or intolerant to DAAs.

Competitive Lifecycle and Replacement Trends

DAAs such as sofosbuvir, ledipasvir, and velpatasvir dominate the hepatitis C treatment landscape due to higher cure rates, shorter treatment durations, and fewer side effects. These drugs have reduced the clinical and commercial relevance of peginterferon alfa-2b, leading to a decline in prescriptions and sales.

Market Size and Segmentation

The global market for interferon therapies in hepatitis had been valued at approximately USD 1.2 billion in 2017. Post-2018, its value contracted sharply, as the focus shifted entirely toward DAA regimens. Current estimates suggest that peginterferon alfa-2b accounts for less than 10% of the overall hepatitis treatment market, primarily used in specific cases where DAA therapy fails or is contraindicated.

Geographic Variability

Developed markets, notably North America and Western Europe, have largely phased out peginterferon in favor of DAAs. Developing regions, including parts of Asia and Africa, still use interferons due to cost factors and limited access to newer medications. This creates a niche market with limited growth potential.

Pricing and Reimbursement Trends

Pricing for peginterferon alfa-2b has decreased due to competition from generics and lower-cost biosimilars. Reimbursement policies further restrict its use, favoring newer, better-tolerated treatments.

Patent and Biosimilar Landscape

Pfizer’s patent protections for PegIntron expired in 2017 in the U.S. and Europe, allowing biosimilar entries. Multiple biosimilars entered markets from 2018 onward, intensifying price competition and reducing revenues.

What Is the Financial Trajectory for Peginterferon Alfa-2b?

Revenue Trends

The global sales of peginterferon alfa-2b peaked around USD 1.2 billion before 2018. Since then, sales have declined sharply; for instance, Pfizer reported global sales of PegIntron in 2016 exceeding USD 900 million, which had fallen below USD 300 million by 2021. Market analysts project continued erosion due to diminishing use and biosimilar entry.

Profitability Outlook

Reduced demand and increased competition from biosimilars have suppressed profit margins. Manufacturing costs remain stable, but pricing pressure has led to declining profitability. Pfizer’s early exit strategies from interferon markets signal shrinking profitability.

R&D and Pipeline Considerations

Pfizer and other manufacturers have deprioritized R&D investments in interferon-based therapies. Emerging pipeline developments focus on combination biologics or newer small-molecule agents for hepatitis and other indications, not peginterferon alfa-2b itself.

Long-term Market Projection

Industry forecasts suggest the peginterferon alfa-2b market will continue contracting through the next decade. Some analysts project revenues could fall below USD 50 million globally by 2030, confined to narrow clinical niches.

Strategic Business Decisions

Pharmaceutical companies are divesting their interferon portfolios or focusing on biosimilar development to sustain revenue streams. Pfizer’s sale of PegIntron’s manufacturing rights and discontinuation in some markets reflect strategic realignment.

Summary of Market and Financial Trends

Parameter	2017	2021	2030 Projection
Global sales	USD 1.2 billion	USD < 300 million	USD < 50 million
Market share in hepatitis treatment	Dominant (60%)	<10%	Niche market
Number of biosimilars in market	None	Several active	Several, market dominance
R&D investment	Steady	Reduced	Minimal

What Are the Key Takeaways?

• The use of peginterferon alfa-2b in hepatitis treatment has declined sharply due to DAA therapies.
• Market revenues have contracted from over USD 1 billion pre-2018 to below USD 300 million currently.
• Biosimilar competition and generics have driven prices and margins downward.
• Continued decline is projected, narrowing the drug’s clinical niche to resistant or contraindicated cases.
• Manufacturers are likely to divest or minimize R&D, focusing on biosimilars or alternative biologics.

What Are the Common Questions?

1. Why did peginterferon alfa-2b lose market share?
Because DAAs provide higher cure rates, shorter regimens, and fewer side effects, replacing interferons in most hepatitis treatments.

2. Are there markets still purchasing peginterferon alfa-2b?
Yes, primarily in developing regions where cost remains a barrier to DAA access, but these markets are shrinking.

3. Will peginterferon alfa-2b return to prominence?
Unlikely. The shift toward oral, well-tolerated, and highly effective therapies has permanently reduced interferons' role.

4. How does biosimilar entry impact the market?
It results in price competition, lower revenues, and manufacturer exit from the market segment.

5. Are there any new indications for peginterferon alfa-2b?
Current evidence does not point to expanded indications; its use remains confined largely to specific hepatitis cases.

References

1. FDA. "PegIntron (peginterferon alfa-2b) approval history."
2. Pfizer Inc. Annual Reports 2016–2021.
3. MarketsandMarkets. "Biologics Market by Type, Application, and Region." 2022.
4. European Medicines Agency. "Hepatitis treatment guidelines." 2019.
5. IQVIA. "Global Hepatitis Market Analysis." 2022.